The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid ...
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...